What is Halozyme Therapeutics's market cap?

Halozyme Therapeutics (HALO) has a market capitalization of $9.7B and trades on NASDAQ.

What is Halozyme Therapeutics's revenue and profitability?

Halozyme Therapeutics generated $1.5B in trailing twelve-month revenue with net income of $608.5M, representing a net margin of 47.9%. Gross margin stands at 82.8%, with free cash flow of $667.7M. These figures are based on the Q1 2026 filing.

Who are Halozyme Therapeutics's competitors?

Halozyme Therapeutics's key competitors include Amphastar Pharmaceuticals, West Pharmaceutical Services, Opko Health Inc., and others. These companies compete in similar markets and product categories.

Who does Halozyme Therapeutics partner with?

Halozyme Therapeutics's notable partners include Roche, Takeda, Janssen, and others.

What subsidiaries does Halozyme Therapeutics have?

Halozyme Therapeutics's subsidiaries include Halozyme Hypercon, Inc..

Where is Halozyme Therapeutics headquartered?

Halozyme Therapeutics is headquartered in United States of America and employs approximately 373 people. It has been publicly traded since 2004.

Halozyme Therapeutics

HALO

Halozyme Therapeutics is a biopharmaceutical company specializing in disruptive drug delivery technologies that convert intravenous therapies into subcutaneous injections.

Market cap

$9.66B+30.5%

Revenue$1.5B+39.1%

Net income$608.5M+37.0%

Free cash flow$667.7M+34.7%

EPS (diluted)$4.91+43.2%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 11, 2026

Revenue$376.7MBeat by $18.1M EPS$1.60Beat by $0.06

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$402.3M

EPS estimate$1.82

Financials

Q1 2026

Income statement

See full

Revenue$376.7M+42.2%

Gross profit$297.5M+37.4%

Operating income$184.5M+30.4%

Net income$150.0M+27.1%

EPS (diluted)$1.22+31.2%

Balance sheet

See full

Cash & equivalents$312.0M+76.9%

Total debt$2.2B+41.7%

Total equity$219.6M-54.5%

Total assets$2.7B+21.7%

Cash flow

See full

Operating cash flow$180.1M+16.8%

CapEx$3.7M+294%

Free cash flow$176.3M+15.0%

Valuation & ratios

Valuation

See full

Market cap$9.66B+30.5%

Enterprise value$11.53B+34.2%

P/E15.9×—

P/S6.4×+0.4×

Profitability

See full

Gross margin82.8%-0.7pp

FCF margin44.3%-1.5pp

Returns & leverage

See full

Debt / equity9.9×+6.7×

Current ratio2.8×-5.6×

Segments

By product

See full

Royalties$240.7M+43.1%

Bulk rHuPH20 sales$73.5M+172%

Proprietary product sales$41.9M+15.2%

Device partnered product sales$15.1M+2.6%

Device licensing and development revenue$5.6M+64.4%

Competitors

By market cap

West Pharmaceutical Services$23.3B+25.8%

Halozyme Therapeutics$9.7B+35.9%

AptarGroup$8.5B-18.8%

Opko Health$936.3M-12.5%

AMP

Amphastar Pharmaceuticals$845.7M-19.3%

Aquestive Therapeutics, Inc.$468.0M+17.8%

Rani Therapeutics Holdings, Inc.$91.0M+279%

Ensysce Biosciences, Inc.$4.0M-26.0%

By revenue growth

Halozyme Therapeutics+39.1%

West Pharmaceutical Services+12.4%

AptarGroup+9.0%

AMP

Amphastar Pharmaceuticals-1.4%

Aquestive Therapeutics, Inc.-7.3%

Opko Health-11.5%

By net margin

Halozyme Therapeutics47.91%-0.6pp

West Pharmaceutical Services16.98%+0.5pp

AMP

Amphastar Pharmaceuticals11.0%-8.4pp

AptarGroup9.98%-0.4pp

Opko Health-12.4%+14.3pp

Aquestive Therapeutics, Inc.-137.08%-37.1pp

Profile

Halozyme Therapeutics is a biopharmaceutical company specializing in disruptive drug delivery technologies that convert intravenous therapies into subcutaneous injections. The company's core value proposition centers on its proprietary ENHANZE platform, which utilizes a recombinant human enzyme to improve patient experiences by reducing treatment burden and enabling at-home administration. Halozyme operates primarily through a high-margin licensing and royalty model, partnering with leading global pharmaceutical firms to co-formulate their proprietary compounds with its delivery technologies.

Competitive position

Halozyme is a market leader in subcutaneous drug delivery conversion, holding a dominant position through its commercially validated ENHANZE technology and an extensive patent portfolio.

GeographiesUnited States, European Union, Japan, China, Canada

Customer segmentsGlobal Pharmaceutical Enterprises, Healthcare Providers, Wholesale Distributors

Business modelLicensing and Royalties, B2B Partnership, Direct-to-Market Product Sales

SuppliersContract Manufacturing Organizations (CMOs), Specialized component suppliers, Raw material providers for recombinant enzymes

CustomersGlobal biopharmaceutical partners, Wholesale pharmaceutical distributors, Specialty pharmacies, Hospitals and surgery centers

CountryUnited States of America

Listed2004

Employees373.0

CEOHelen I. Torley

SectorHealthcare

IndustryBiotechnology

Websitehalozyme.com

FilingsSEC EDGAR

Ask your AI about Halozyme Therapeutics.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Halozyme Therapeutics's market cap?: Halozyme Therapeutics (HALO) has a market capitalization of $9.7B and trades on NASDAQ.
What is Halozyme Therapeutics's revenue and profitability?: Halozyme Therapeutics generated $1.5B in trailing twelve-month revenue with net income of $608.5M, representing a net margin of 47.9%. Gross margin stands at 82.8%, with free cash flow of $667.7M. These figures are based on the Q1 2026 filing.
Who are Halozyme Therapeutics's competitors?: Halozyme Therapeutics's key competitors include Amphastar Pharmaceuticals, West Pharmaceutical Services, Opko Health Inc., and others. These companies compete in similar markets and product categories.
Who does Halozyme Therapeutics partner with?: Halozyme Therapeutics's notable partners include Roche, Takeda, Janssen, and others.
What subsidiaries does Halozyme Therapeutics have?: Halozyme Therapeutics's subsidiaries include Halozyme Hypercon, Inc..
Where is Halozyme Therapeutics headquartered?: Halozyme Therapeutics is headquartered in United States of America and employs approximately 373 people. It has been publicly traded since 2004.